Company news

Monte Rosa Therapeutics, Inc. news in 2026

Monte Rosa Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Monte Rosa Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates

November 5, 2026

Monte Rosa Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 3, 2026

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

November 2, 2026

Monte Rosa Therapeutics Announces Milestone Achievement Associated with Second Phase 2 Clinical Study Initiation for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)

October 28, 2026

Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 2, 2026

Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk

October 1, 2026

Monte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease Risk

September 30, 2026

Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)

September 8, 2026

Monte Rosa Therapeutics Announces First Patient Dosed in MODeFIRe-1, a Phase 2 Study of MRT-2359 in Combination with Apalutamide in Patients with AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer

August 24, 2026

Monte Rosa Therapeutics: Q2 Earnings Snapshot

August 6, 2026

Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates

August 6, 2026

Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates

May 7, 2026

Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 5, 2026

Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors

April 20, 2026

Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates

March 16, 2026

Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer

March 15, 2026

Monte Rosa Therapeutics Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients at ASCO Genitourinary Cancers Symposium (ASCO GU)

February 23, 2026

Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering

January 8, 2026

Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

January 7, 2026

Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects

January 7, 2026

Monte Rosa Therapeutics to Present Interim MRT-8102 Phase 1 Study Results

January 6, 2026

Decks in 2026